The Next GLP-1 Moment? Why Big Pharma Is Investing in Depression Only a few years ago, psychedelic medicine sat on the fringes of pharmaceutical research. Today, it has become one of the industry’s fastest-growing investment areas. In July, Eli Lilly announced a $2.8 billion acquisition of Atai Beckley, gaining access to BPL-003, an intranasal 5-MeO-DMT therapy for treatment-resistant depression. It wasn’t an isolated move. Johnson & Read more
Clinical Research Focus. 55th Edition Clinical Research Focus featuring topical articles of interest to the clinical trial community. Explore the news of July 2026. Read more
lung cancer breakthroughs
World Lung Cancer Day: Four Breakthroughs Worth Watching in 2026 As World Lung Cancer Day approaches, it’s an opportunity to reflect not only on the challenges that remain, but also on how quickly lung cancer research is advancing. Lung cancer remains the leading cause of cancer-related death worldwide. In the US alone, an estimated 229,410 people will be diagnosed and nearly 125,000 will die from Read more
The $137 Billion Wake-Up Call: What Operation TrialBlazer Really Changes for Sponsors The US Department of Health and Human Services launched Operation TrialBlazer, one of the most ambitious clinical research initiatives in years. While many of its proposals are still under consultation, the message is clear: the US wants to accelerate clinical development and strengthen its global competitiveness. Why now A few numbers explain why HHS is Read more

Schedule a meeting

We are excited to connect with you, understand your goals, and explore how we can support your needs.

Contact us